Koji Horie

Koji Horie

Auto-generated profile, based on publicly available information

Koji Horie

Department of Gynecology, Saitama Cancer Center, Saitama, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YKYosuke Konno
Yosuke Konno
HAHiroshi Asano
Hiroshi Asano
ASAyumi Shikama
Ayumi Shikama
DADaisuke Aoki
Daisuke Aoki
MTMichihiro Tanikawa
Michihiro Tanikawa
Hidemichi WatariHidemichi Watari
Hidemichi Watari
Konno Y, et al. J Gynecol Oncol. 2021 Jan;32(2):e25. https://doi.org/10.3802/jgo.2021.32.e25

9 June 2021 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
AKAtsushi Kihara
Atsushi Kihara
TIToshihiko Iizuka
Toshihiko Iizuka
SEShinichi Endo
Shinichi Endo
KHKoji Horie
Koji Horie
HKHiroaki Kanda
Hiroaki Kanda
TNToshiro Niki
Toshiro Niki

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
Shin NishioShin Nishio
Shin Nishio
KUKimio Ushijima
Kimio Ushijima
MIMitsuya Ishikawa
Mitsuya Ishikawa
HTHideki Tokunaga
Hideki Tokunaga
KHKoji Horie
Koji Horie
JGJapanese Clinical Oncology Group (JCOG) Gynecologic Cancer Study Group
Japanese Clinical Oncology Group (JCOG) Gynecologic Cancer Study Group
Nishio S, et al. J Gynecol Oncol. 2025 Mar;36:e93. https://doi.org/10.3802/jgo.2025.36.e93

20 May 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MTMunetaka Takekuma
Munetaka Takekuma
FTFumiaki Takahashi
Fumiaki Takahashi
SMSeiji Mabuchi
Seiji Mabuchi
WKWataru Kudaka
Wataru Kudaka
KHKoji Horie
Koji Horie
NYNobuo Yaegashi
Nobuo Yaegashi
5527 Background: Patients with persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy (RT/CCRT) have a poor prognosis. Salvage hysterectomy (HT) is considered curative treatment; however, very little data exists showing the survival advantage of HT over standard therapy. Methods: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005–2014 were reviewed retrospectively. Those who underwent a HT for residual cervical disease after definitive RT/CCRT were matched (histology, FIGO stage at initial treatment, brachytherapy application, age and performance status at diagnosis of residual tumor, diameter and parametrial invasion by residual tumor, and the number of lymph node tumors at diagnosis, etc.) with propensity scores for patients who underwent systemic chemotherapy (CT). Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. Results: A total of 142 patients with residual cervical disease after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). A difference in all background factors between HT and CT groups was not observed. At a median follow-up of 4.6 years, 33 (46.5%) and 47 deaths (66.2%) occurred in HT and CT groups, respectively. Median overall survival was 3.8 and 1.5 years in HT and CT groups, respectively (p= 0.0019, hazards ratio [HR] 2.438, 95% confidence interval [CI] 1.362–4.361), and median progression-free survival was 2.7 and 0.7 years, respectively (p= 0.0046, HR 2.235, 95% CI 1.262–3.960). Increasing tumor size was significantly associated with a high incomplete resection rate (p= 0.0385, Odds Ratio 0.941, 95% CI 0.888–0.997). The cut-off value for the residual tumor diameter regarding complete resection after receiver operating characteristic (ROC) analysis was 11 mm (sensitivity 70%, specificity 86.9%). Conclusions: Salvage HT may be considered curative treatment for patients with residual cervical disease after definitive RT/CCRT. The diameter of residual tumor is important in selecting appropriate candidates for HT.

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MIMitsuya Ishikawa
Mitsuya Ishikawa
RKRyo Kitagawa
Ryo Kitagawa
TSTaro Shibata
Taro Shibata
HTHideki Tokunaga
Hideki Tokunaga
TITakashi Iwata
Takashi Iwata
NYNobuo Yaegashi
Nobuo Yaegashi
6027 Background: A randomized controlled trial was conducted to assess the efficacy and safety of dose-dense, weekly paclitaxel plus carboplatin (ddTC) with or without bevacizumab (Bmab) compared to conventional, tri-weekly paclitaxel plus carboplatin (cTC) with or without Bmab, in metastatic or recurrent cervical carcinoma not amenable to curative treatments with local therapy. Methods: Patients were randomly assigned to either a cTC or a ddTC regimen. After Bmab was approved in Japan (in May 2016) the protocol was amended, and patients on both arms received Bmab if not contraindicated. The cTC was paclitaxel 175 mg/m2 intravenously (IV) for 3 h on day 1 followed by carboplatin at an area under the curve of five IV for 1 h on day 1. The ddTC was paclitaxel 80 mg/m2 IV for 1 h on day 1 followed by carboplatin at an area under the curve of five IV for 1 h on day 1 and paclitaxel 80 mg/m2 IV for 1 h on day 8 and day 15. Both cTC and ddTC treatments were repeated every three weeks, for up to nine cycles. Bmab 15 mg/kg IV was repeated until progression or unacceptable toxicity. The primary endpoint of phase II was the response rate (RR) in patients with measurable lesion, who had received Bmab. If the RR of the ddTC + Bmab arm was greater than that of the cTC + Bmab arm for more than 5%, the study would proceed to phase III, which had overall survival (OS) as its primary endpoint. The planned sample size in the phase II part was 56 to select the ddTC arm with a probability of at least 75% if the difference of RR was 15% or more (45% vs. 60%). Results: Patient accrual started in October 2015. It was suspended in May 2019 because the number of Bmab-treated patients with measurable lesions reached 56. In total, 122 patients were enrolled and randomly assigned to either the cTC arm (cTC: 29 patients; cTC + Bmab: 32 patients) or the ddTC arm (ddTC: 30 patients; ddTC + Bmab: 31 patients). The primary analysis of the phase II part was conducted in November 2019. The RRs of each regimen were 67.9% [95% CI, 47.7-84.1] (19/28, cTC + Bmab), 60.7% [40.6-78.5] (17/28, ddTC + Bmab), 55.2% [35.7-73.6] (16/29, cTC), and 50.0% [29.9-70.1] (13/26, ddTC). Conclusions: The study did not meet the primary endpoint of phase II. Dose-dense, weekly paclitaxel plus carboplatin is not promising for metastatic or recurrent cervical carcinoma. Clinical trial information: jRCTs031180007.

17 December 2025 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MGMayuko Goda
Mayuko Goda
GYGou Yamamoto
Gou Yamamoto
KIKatsuya Iuchi
Katsuya Iuchi
KHKoji Horie
Koji Horie
KAKiwamu Akagi
Kiwamu Akagi